SITC Summit on the Future of Neoadjuvant Clinical Trial Design Thursday, June 26, 2025: 11 a.m.–3 p.m. EDT |
11–11:05 a.m. EDT |
Welcome Patrick Forde, MD – Trinity College Dublin |
Session I: Neoadjuvant and Perioperative Immunotherapy |
11:05–11:20 a.m. EDT |
Introductory talk Paz Vellanki, MD, PhD – FDA |
11:20–11:35 a.m. EDT |
Industry perspective on the contribution of phases in the neoadjuvant and perioperative settings Leora Horn, MD – AstraZeneca Harpreet Singh, MD – Precision for Medicine |
11:35–11:50 a.m. EDT |
Future clinical trial design in the neoadjuvant and perioperative setting John Heymach, MD, PhD – The University of Texas MD Anderson Cancer Center |
11:50 a.m.–12:05 p.m. EDT |
Endpoints and making decisions about treatment Solange Peters, MD, PhD – Lausanne University and ESMO |
12:05–12:20 p.m. EDT |
Panel discussion All session speakers, moderated by Dr. Forde |
Session II: Clinical Trials of Neoadjuvant and Perioperative Immunotherapy |
12:20–12:40 p.m. EDT |
Statistician point-counterpoint Megan Othus, PhD – Fred Hutchinson Cancer Center Pallavi Mishra-Kalyani, PhD – FDA |
12:40–12:50 p.m. EDT |
Lessons learned from the NeoCOAST trials Tina Cascone, MD, PhD – The University of Texas MD Anderson Cancer Center |
12:50–1 p.m. EDT |
Surgeon perspective Neil Gross, MD – The University of Texas MD Anderson Cancer Center |
1–1:20 p.m. EDT |
Panel discussion All session speakers and Brittany McKelvey, PhD – LUNGevity |
1:20–1:35 p.m. EDT |
Break |
Session III: Neoadjuvant and Perioperative Therapy Across Cancer Types |
Part A: Disease experts give quick burst talks showcasing state-of-the-art data in a specific cancer type |
1:35–1:55 p.m. EDT |
Hepatocellular carcinoma Mark Yarchoan, MD – Johns Hopkins University
Esophageal/gastric cancer Ronan Kelly, MD, MBA, FASCO – Baylor University Medical Center
MSI-high colorectal cancers Michael Overman, MD – The University of Texas MD Anderson Cancer Center
Merkel cell carcinoma Shailender Bhatia, MD – University of Washington
Urothelial cancer Thomas Powles, MBBS, MD, MRCP – Queen Mary University of London
Head and neck cancers Ravi Uppaluri, MD, PhD – Dana-Farber Cancer Institute/Brigham and Women's Hospital |
Part B: Pathologist Perspective |
1:55–2:10 p.m. EDT |
Pathologist perspective Janis Taube, MD – Johns Hopkins University |
Part C: Panel Discussion |
2:10–2:55 p.m. EDT |
Panel discussion All session speakers, moderated by Dr. Forde |
2:55–3:00 p.m. EDT |
Closing remarks Patrick Forde, MD – Trinity College Dublin |